Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Par files for IPO

This article was originally published in Scrip

Executive Summary

Par Pharmaceutical has filed a registration statement with the US Securities and Exchange Commission for an initial public offering of up to $100m. The Chestnut Ridge, New York company specializes in harder to make generics (or those that face complex regulatory challenges) and also has two branded specialty pharma products: the hormonal anticancer therapy Megace (megestrol acetate) and Nascobal (cyanocobalamin, USP) vitamin B12 nasal spray. The company has not decided the size and timing of the offering, but it intends to use the proceeds primarily to pay down debt. In December 2014 long-term debt totalled $1.9bn. Revenues in 2014 were $1.3bn, and the firm booked a net loss of $106m. Last year it agreed to pay $100m to settle a patent dispute with Salix Pharmaceuticals over the latter's oral proton-pump inhibitor Zegerid, an immediate-release form of omeprazole plus sodium bicarbonate.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts